BD MedMined™ Surveillance Advisor has earned Meaningful Use Stage 3 (MU3) certification validating its ability to collect and properly report data around antimicrobial use and resistance data by facilities enrolled in the National Healthcare Safety Network (NHSN) that requires reporting for Antimicrobial Use and Resistance (AUR) data in 2018.
Public Health Registry Reporting is a new option for MU3, requiring AUR data to help the Centers for Disease Control and Prevention (CDC) to gain a better understanding of how antibiotic usage impacts resistance in hospitals and healthcare facilities. The objective calls for reporting a full calendar year’s data on R1 Normative Antimicrobial Use Summary, Antimicrobial Resistance Event, and Antimicrobial Resistance summary data to be reported using clinical documentation architecture (CDA) formatting.
By submitting AUR data into the NHSN platform, clinicians can benchmark their antibiotic usage and organisms resistance data nationally to target areas for improvement.
By leveraging data from a hospital’s electronic medical record, physician order entry, laboratory and pathology systems to monitor patients for adverse drug events and interactions, BD MedMined can alert clinicians and pharmacists to potential adverse events across the continuum of care.
“This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services.”
This certified product-version requires a one-time implementation fee and an annual licensing fee. This certified product-version is certified to data export criteria 170.315(f)(6) and can generate Antimicrobial Use and Resistance CDA reports. Technical Limitations: None to Report
Beckton Dickinson and Company
400 Vestavia Parkway, Suite 310 Birmingham, AL 35216
Contact: Ania Bradford
Product Name: AUR Reporting Module, Version 1
Testing Location: Web session with InfoGard Laboratories, New Certification
170.315(d)(1)-170.315(d)(3), 170.316(d)(7), 170.315(f)(6), 170.315 (g)(4), 170.315 (g)(5)
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.